Form 4: Precision BioSciences Director Receives RSU Grant

Director Geno J. Germano was granted 20,979 restricted stock units as part of the company's equity compensation program.

Summary

• Director Geno J. Germano received a grant of 20,979 restricted stock units (RSUs) on June 3, 2026.
• Each RSU represents a contingent right to receive one share of Precision BioSciences common stock.
• The RSUs are subject to a vesting schedule tied to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is contingent upon the director's continued service to the company.

Future Outlook

The RSUs will vest on the earlier of June 3, 2027, or the day prior to the next annual meeting of stockholders, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The vesting period of approximately one year is typical for annual director equity refresh grants.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of the 20,979 RSUs on or before June 3, 2027.

Key Dates

Keywords

Precision BioSciences, DTIL, Form 4, Insider Trading, Equity Compensation, Director Compensation